查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018631

伴侶動物術後疼痛管理治療市場：依產品種類、動物種類、給藥途徑及最終使用者分類－2026年至2032年全球市場預測

Companion Animal Postoperative Pain Management Therapeutics Market by Product Type, Animal Type, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，伴侶動物術後疼痛管理療法的市值為 1.6465 億美元，預計到 2026 年將成長至 1.8638 億美元，複合年成長率為 10.36%，到 ​​2032 年將達到 3.2845 億美元。

主要市場統計數據
基準年 2025 1.6465億美元
預計年份：2026年 1.8638億美元
預測年份 2032 3.2845億美元
複合年成長率 (%) 10.36%

對影響伴侶動物術後疼痛管理的臨床、技術和商業性發展趨勢進行了權威概述。

伴侶動物術後疼痛管理已從單一的臨床問題發展成為一項涵蓋藥理學、手術方案設計和飼主教育的多學科挑戰。臨床醫生如今需要在療效、安全性和飼主依從性之間取得平衡，同時還要應對日益嚴格的鴉片類藥物使用監管和不斷湧現的替代療法選擇。因此，治療決策不僅要考慮犬貓的急性疼痛緩解需求，還要兼顧長期福利、診所的財務狀況以及供應鏈的實際情況。

臨床方案的演變、製劑的突破性進展以及分銷管道的變化如何重新定義伴侶動物的術後疼痛管理。

伴侶動物術後疼痛管理領域正經歷一場變革，這得益於臨床實務、技術和經銷領域多項創新成果的融合。臨床上，多因子鎮痛方案正被加速採用，這些方案結合了局部麻醉劑、非類固醇消炎劑和選擇性鴉片類藥物，旨在最佳化疼痛管理並最大限度地減少副作用。這一轉變體現了人們對疼痛病理生理學的更深入理解，以及向循證、個體化的圍手術全期計劃邁進的趨勢。

2025 年關稅措施對伴侶動物鎮痛藥的採購、定價結構和庫存策略的綜合影響。

2025年起實施的累積關稅為獸藥相關人員的供應鏈和成本管理帶來了新的複雜性。關稅帶來的成本壓力迫使生產商和經銷商重新評估籌資策略，優先考慮區域供應穩定，並盡可能考慮將特定生產流程轉移到國內或近岸地區。因此，採購團隊越來越注重供應商多元化，以降低供應來源集中和關稅波動帶來的風險。

差異化細分分析揭示了產品類型、動物種類、給藥途徑和分銷管道結構如何獨特地影響臨床應用和商業策略。

對術後鎮痛生態系統的詳細細分和分析揭示了臨床應用、製劑偏好和分銷管道趨勢方面的顯著差異，這些差異正在推動差異化的商業策略。就產品類型而言，該領域主要圍繞局部麻醉劑、非類固醇消炎劑（ NSAIDs）和鴉片類藥物展開，每種藥物都具有獨特的治療作用和監管考慮。在局部麻醉劑中，Bupivacaine和Lidocaine等藥物用於術中和術後即刻鎮痛，緩釋製劑的進步進一步提升了它們的戰略價值。包括卡洛芬、德拉考昔、非羅考昔和美洛昔康在內的非類固醇非類固醇消炎劑是術後疼痛和發炎管理的核心，儘管它們的安全性和給藥方法有所不同。Buprenornhine、Fentanyl和曲馬多等鴉片類藥物在中重度疼痛治療中仍然發揮著重要作用，但它們面臨著日益嚴格的管理框架，這影響著處方行為。

各地區在法規、臨床實踐和分銷管道成熟度方面的差異，決定了每個全球市場進入、商業化和生命週期策略的差異化。

區域趨勢對法規環境、流通結構和臨床實踐規範有著顯著影響，從而在美洲、歐洲、中東、非洲和亞太地區創造了不同的機會。在美洲，完善的獸醫基礎設施和寵物飼主較高的消費水準促進了先進配方和綜合圍手術全期方案的快速普及，但報銷模式仍以自費為主，因此對產品價值的感知更為敏感。在這種環境下，透過便利性、安全性以及能夠引起臨床醫生和飼主共鳴的顯著療效來實現差異化，將具有顯著優勢。

現有製藥公司、專業創新者和策略夥伴如何合作，以推動術後鎮痛領域的臨床引入、分銷管道的拓展和產品差異化？

伴侶動物術後鎮痛領域的競爭格局呈現出多元化的特點，既有成熟的製藥公司，也有專注於獸藥創新和製劑及給藥方式創新的新興生物製藥公司。成熟公司憑藉其廣泛的分銷網路和與臨床醫生的良好關係，在醫院和零售通路中保持著穩固的地位。同時，專業公司則透過突破性的緩釋技術、經皮吸收系統以及簡化手術全期工作流程的產品支援服務，在競爭中脫穎而出。

為了獲得競爭優勢，製藥公司和經銷商需要採取切實可行的策略措施，以協調證據產生、配方設計、供應彈性和通路整合。

產業領導企業應採取一致且以證據主導的策略，將產品創新與臨床方案和通路實際情況結合，以確保永續的競爭優勢。其中，應優先創建多模態臨床證據，以證明局部麻醉劑、非類固醇抗發炎藥和選擇性鴉片類藥物的聯合應用如何改善患者預後並降低併發症率。基於真實世界環境的高品質臨床試驗以及真實世界數據的收集，不僅能夠增強醫院和診所的價值提案，還能支持負責任的藥物管理理念。

採用穩健的混合方法研究途徑，結合臨床醫生訪談、文獻整合和基於細分的場景分析，以檢驗對該行業的見解。

本執行摘要所依據的研究結合了多種定性和定量方法，旨在全面了解臨床、商業和監管趨勢。主要研究包括對獸醫、全科醫生、處方集管理人員和分銷主管進行結構化訪談，以了解臨床實踐中的處方行為、分銷管道偏好和營運限制。次要研究廣泛涵蓋了同行評審的獸醫臨床文獻、監管指導文件以及公開的製劑和藥物安全監測報告，以闡明產品層面的考慮因素和安全性概況。

本文簡明扼要地整合了臨床創新、監管預期和商業性實施，概述了未來的策略重點。

伴侶動物術後疼痛管理正處於轉折點，臨床最佳實踐、製劑技術的進步以及不斷發展的銷售管道相互交匯，為相關人員創造了新的機會和責任。朝向多面向鎮痛的轉變，以及緩釋局部麻醉劑和經皮製劑系統的創新，增強了提供有效且便於飼主的疼痛管理的能力。同時，監管機構對合理使用鴉片類藥物的重視以及不斷變化的定價結構，要求採用更完善的供應鏈和臨床管治方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 伴侶動物術後疼痛管理治療市場：依產品類型分類

  • 局部麻醉劑
    • Bupivacaine
    • Lidocaine
  • 非類固醇消炎劑
    • 卡洛芬
    • 德拉考昔
    • 菲洛昔布
    • 美洛昔康
  • 鴉片類藥物
    • Buprenornhine
    • Fentanyl
    • 特拉馬多爾

第9章 伴侶動物術後疼痛管理治療市場：依動物類型分類

  • 貓
  • 狗

第10章：伴侶動物術後疼痛管理治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用
  • 經皮吸收貼片

第11章 伴侶動物術後疼痛管理治療市場：依最終使用者分類

  • 網路藥房
  • 獸醫醫院和診所
    • 一般診所
    • 專科醫院
  • 獸用零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章 伴侶動物術後疼痛管理治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 伴侶動物術後疼痛管理治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 伴侶動物術後疼痛管理治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國伴侶動物術後疼痛管理治療市場

第16章：中國伴侶動物術後止痛治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Addison Biological Laboratory Inc.
  • Assisi Animal Health
  • Avazzia
  • Bayer AG
  • Bimeda Animal Health
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Ceva Sante Animale
  • Chanelle Pharma Group
  • Daiichi Sankyo Co. Ltd.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Eltech K-Laser SRL
  • Fidelis Pharmaceuticals, LLC
  • Merck & Co.
  • Multi Radiance Medical
  • Norbrook Laboratories
  • Richter Pharma AG
  • SAVA Vet
  • Sequent Scientific Ltd.
  • VETINDIA Pharmaceuticals Limited
  • Vetoquinol SA
  • Virbac Group
  • Virpax Pharmaceuticals Inc.
  • Zoetis Inc.
Product Code: MRR-221461476CB6

The Companion Animal Postoperative Pain Management Therapeutics Market was valued at USD 164.65 million in 2025 and is projected to grow to USD 186.38 million in 2026, with a CAGR of 10.36%, reaching USD 328.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 164.65 million
Estimated Year [2026] USD 186.38 million
Forecast Year [2032] USD 328.45 million
CAGR (%) 10.36%

An authoritative orientation to the evolving clinical, technological, and commercial dynamics shaping postoperative pain therapies for companion animals

Companion animal postoperative pain management has evolved from a narrow clinical concern into a multidisciplinary imperative that spans pharmacology, surgical protocol design, and client education. Clinicians now balance efficacy, safety, and owner compliance while navigating heightened regulatory scrutiny around opioid use and a growing portfolio of alternatives. Consequently, therapeutic decision-making reflects not only the acute analgesic needs of cats and dogs but also longer-term welfare considerations, practice economics, and supply chain realities.

In parallel, advances in formulation technologies, such as extended-release local anesthetics and transdermal systems, are changing perioperative workflows and enabling more predictable analgesia with fewer administrations. These technical developments intersect with evolving practice settings; specialty hospitals, growing online pharmacy channels, and multi-site veterinary groups shape how products are prescribed, dispensed, and monitored. Therefore, stakeholders must synthesize clinical evidence, route-of-administration preferences, and end-user behaviors to design commercially viable and clinically effective strategies.

This report executive summary situates these dynamics within the broader therapeutic landscape for postoperative pain in cats and dogs, highlighting the clinical drivers, product innovation trajectories, and structural industry shifts that influence adoption. The aim is to equip decision-makers with an integrated perspective that supports tactical planning across R&D, regulatory engagement, and commercial execution.

How clinical protocol evolution, formulation breakthroughs, and shifting distribution channels are redefining postoperative pain management for companion animals

The landscape of postoperative pain management in companion animals is undergoing transformative shifts driven by converging clinical, technological, and distribution innovations. Clinically, there is an accelerating adoption of multimodal analgesia protocols that combine local anesthetics, non-steroidal anti-inflammatory drugs, and selective opioid use to optimize pain control while mitigating side effects. This shift represents a more nuanced appreciation of pain pathophysiology and a move toward individualized perioperative plans anchored in evidence-based practice.

Technologically, formulation science is delivering longer-acting local anesthetics and improved transdermal and injectable delivery systems, which reduce dosing frequency and improve owner adherence. These advances enable smoother transitions from hospital to home care and open opportunities for novel product positioning centered on convenience and sustained efficacy. Simultaneously, safety-focused innovation in NSAID chemistry and labeling, combined with better clinician education, is reducing adverse-event concerns that historically limited aggressive postoperative management.

On the commercial side, distribution and access are changing as online pharmacies gain traction alongside traditional veterinary hospitals and retail pharmacies. This diversification of channels compels manufacturers to adopt more sophisticated supply chain and pricing strategies. In addition, regulatory trends emphasizing opioid stewardship and post-market pharmacovigilance are reshaping product lifecycle planning. Taken together, these shifts create a more complex but opportunity-rich environment where clinical credibility, formulation differentiation, and channel-aligned commercialization determine success.

The compound effects of 2025 tariff measures on pharmaceutical sourcing, pricing architecture, and inventory strategies for companion animal analgesics

The introduction of cumulative tariffs in 2025 has added a new layer of complexity to supply chains and cost management for veterinary pharmaceutical stakeholders. Tariff-driven cost pressures have prompted manufacturers and distributors to reevaluate sourcing strategies, prioritize regional supply security, and consider onshoring or nearshoring certain manufacturing steps where feasible. As a result, procurement teams are increasingly focused on supplier diversification to reduce exposure to concentrated origin risks and tariff volatility.

These tariff effects propagate beyond direct input costs; they influence pricing negotiations with end-user channels, inventory management practices, and the structure of contractual agreements. Veterinary hospitals and clinics, especially smaller general practices, have had to reassess purchasing cadence and inventory buffers to mitigate price fluctuations. Meanwhile, chain pharmacies and larger specialty hospitals possess greater leverage to negotiate volume-based arrangements that can partially offset tariff-related cost increases.

Moreover, the tariff environment has accelerated conversations about formulation simplification and longer-dated products to rationalize logistics expenses. Transitional strategies include prioritizing products with durable shelf life, increasing the use of extended-release formulations to reduce reorder frequency, and aligning clinical protocols to favor therapies that balance administration complexity with supply resilience. Ultimately, tariff dynamics in 2025 have underscored the need for integrated commercial and supply-chain planning to maintain access and affordability for postoperative pain therapies in companion animals.

A differentiated segmentation analysis revealing how product types, animal species, administration routes, and channel structures uniquely shape clinical adoption and commercial strategy

A granular segmentation view of the postoperative analgesia ecosystem reveals critical variances in clinical use, formulation preference, and channel dynamics that drive differentiated commercial strategies. When considering product type, the field is structured around local anesthetics, non-steroidal anti-inflammatory drugs, and opioids, each with distinct therapeutic roles and regulatory considerations. Within local anesthetics, agents such as bupivacaine and lidocaine address intraoperative and immediate postoperative pain control, and advances in extended-release formulations magnify their strategic value. Non-steroidal anti-inflammatory drugs encompass molecules including carprofen, deracoxib, firocoxib, and meloxicam, which form the backbone of postoperative pain and inflammation management with varying safety profiles and dosing paradigms. Opioids such as buprenorphine, fentanyl, and tramadol maintain a role for moderate to severe pain but face increasingly stringent stewardship frameworks that influence prescribing behavior.

Animal type further stratifies clinical pathways, as cats and dogs exhibit important pharmacologic and behavioral differences that affect agent selection, dosing, and owner instructions. Cats, for instance, require particular attention to certain NSAID tolerability and opioid choice, while dogs benefit from a broader array of approved NSAID options and established perioperative pathways. Route of administration exerts a powerful influence on adoption and compliance; injectable formulations are favored for perioperative control in hospital settings, oral agents support home-based continuation of therapy, topical options address localized pain with lower systemic exposure, and transdermal patches offer extended analgesia suited to outpatient care and owner convenience.

End-user segmentation shapes access, prescribing patterns, and point-of-sale dynamics. Online pharmacies expand reach and convenience but bring considerations around regulatory compliance and clinician engagement. Veterinary hospitals and clinics, including general practices and specialty hospitals, serve as primary decision points for perioperative planning and on-site administration, while veterinary retail pharmacies-both chain and independent-play a critical role in dispensing and counseling at the point of release. These layered segmentation dimensions inform R&D prioritization, commercial targeting, and educational outreach, ensuring that product positioning aligns with the clinical realities and logistical preferences of each stakeholder group.

Regional variations in regulation, clinical practices, and channel maturity that dictate differentiated entry, commercialization, and lifecycle strategies across global markets

Regional dynamics materially influence regulatory environments, distribution architectures, and clinical practice norms, creating divergent opportunity sets across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established veterinary practice infrastructures and high pet-owner spend support rapid uptake of advanced formulations and comprehensive perioperative protocols, while reimbursement models remain largely private-pay and therefore sensitive to perceived value. This environment favors differentiation through convenience, proven safety, and demonstrable outcomes that resonate with clinicians and owners alike.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varying market maturity produce a patchwork of adoption rates. Western European markets often mirror advanced clinical protocols and prioritize pharmacovigilance and labeling harmonization, whereas some markets in the broader region emphasize cost containment and incremental introductions of novel therapies. Regulatory frameworks that emphasize veterinary drug safety and antimicrobial stewardship also shape opioid access and NSAID labeling, influencing product rollouts and educational priorities.

Asia-Pacific presents a mix of fast-evolving companion animal care standards, significant investment in specialty veterinary services, and a rapidly expanding online pharmacy footprint. Certain countries in the region are accelerating clinical guideline adoption and are highly receptive to formulation innovations that reduce dosing frequency and support outpatient care. However, supply-chain complexity and local regulatory idiosyncrasies require targeted market-entry strategies that account for registration timelines, import requirements, and channel partner selection. Navigating these regional nuances is essential for aligning clinical evidence packages and commercialization plans with local expectations and constraints.

How incumbent manufacturers, specialty innovators, and strategic partners converge to drive clinical adoption, channel access, and product differentiation in postoperative analgesia

Competitive dynamics in the companion animal postoperative pain therapeutic area are characterized by a mix of established pharmaceutical manufacturers, specialty veterinary pharma innovators, and emerging biopharmaceutical entrants focused on formulation and delivery innovation. Incumbent players leverage broad distribution networks and clinician relationships to maintain a presence in hospital and retail channels, while specialized companies differentiate through novel extended-release technologies, transdermal systems, and product support services that simplify perioperative workflows.

Strategic activity centers on demonstrating clinical differentiation, securing favorable formulary positions within hospital systems, and forging partnerships with veterinary chains and online distributors. Additionally, companies that invest in robust post-market safety surveillance and targeted clinician education tend to gain trust among practitioners who prioritize predictable risk-benefit profiles. New entrants and smaller specialists often adopt nimble go-to-market approaches, using focused clinical pilots, key opinion leader engagement, and digital education platforms to accelerate adoption.

Collaborative models are increasingly common, with licensing, co-promotion, and distribution agreements enabling faster market access across regions with divergent regulatory hurdles. As commercialization becomes more channel-specific, companies that align product design with end-user preferences-such as favoring injectable extended-release formulations for specialty hospitals or convenient oral regimens for general practices-are better positioned to capture clinical mindshare and long-term loyalty.

Practical strategic moves for manufacturers and distributors to align evidence generation, formulation design, supply resilience, and channel engagement to gain competitive advantage

Industry leaders should adopt a coherent, evidence-driven strategy that aligns product innovation with clinical protocols and channel realities to secure sustainable advantage. First, prioritize multimodal clinical evidence generation that demonstrates how combinations of local anesthetics, NSAIDs, and selective opioid use improve patient outcomes and reduce complication rates. High-quality, practice-embedded trials and real-world data capture will strengthen value propositions for hospitals and clinics while supporting responsible stewardship narratives.

Second, align formulation strategy with end-user workflows by offering extended-release and transdermal options where they reduce dosing burden and improve compliance, and by ensuring injectable profiles support efficient perioperative use. Tailoring packaging, labeling, and educational materials to the needs of general practices versus specialty hospitals will improve uptake and reduce friction at the point of care. Third, develop resilient supply-chain models that account for tariff risk, favor diversified sourcing, and include contingency inventory strategies to maintain continuity of supply during global disruptions.

Fourth, invest in channel-specific commercial models that balance online pharmacy engagement with deep clinical partnerships. Digital education, telemedicine-aligned prescribing support, and clinic-facing decision aids can enhance appropriate product use. Finally, incorporate robust pharmacovigilance and opioid stewardship programs to meet regulatory expectations and build practitioner trust. Together, these measures will enable companies to convert clinical credibility into durable commercial performance while responsibly advancing patient care.

A robust mixed-methods research approach integrating clinician interviews, literature synthesis, and segmentation-driven scenario analysis to validate sector insights

The research underpinning this executive summary combines multiple qualitative and quantitative approaches to ensure a comprehensive understanding of clinical, commercial, and regulatory dynamics. Primary research included structured interviews with veterinary surgeons, general practitioners, formulary managers, and distribution executives to capture real-world prescribing behaviors, channel preferences, and operational constraints. Secondary research encompassed a cross-section of peer-reviewed veterinary clinical literature, regulatory guidance documents, and publicly available formulation and pharmacovigilance reports to contextualize product-level considerations and safety profiles.

Analytical techniques included cross-segmentation synthesis to map how product types, animal species, administration routes, and end-user channels interact, as well as scenario analysis to evaluate supply-chain disruptions and tariff impacts. Validation workshops with practicing clinicians and commercial stakeholders were used to test hypotheses and refine implications for product positioning and go-to-market tactics. Throughout the methodology, emphasis was placed on triangulating insights across multiple data sources to reduce single-source bias and to ensure relevance across diverse regional contexts.

A concise synthesis of convergence between clinical innovation, regulatory expectations, and commercial execution that outlines strategic priorities for the future

Postoperative pain management for companion animals is at an inflection point where clinical best practices, formulation advances, and shifting commercial channels converge to create new opportunities and obligations for stakeholders. The move toward multimodal analgesia, coupled with innovations in extended-release local anesthetics and transdermal delivery systems, enhances the capacity to deliver effective, owner-friendly pain control. At the same time, regulatory emphasis on opioid stewardship and evolving tariff landscapes demand more sophisticated supply-chain and clinical governance approaches.

Successfully navigating this landscape requires integrating rigorous clinical evidence with channel-aware commercialization and resilient sourcing strategies. Companies that invest in clinician engagement, differentiated formulations that solve practical problems, and robust pharmacovigilance frameworks will be better positioned to influence prescribing behavior and to achieve longer-term adoption. In essence, the future of companion animal postoperative analgesia will reward organizations that pair clinical credibility with operational excellence and a clear focus on practitioner and pet-owner needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Postoperative Pain Management Therapeutics Market, by Product Type

  • 8.1. Local Anesthetics
    • 8.1.1. Bupivacaine
    • 8.1.2. Lidocaine
  • 8.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.2.1. Carprofen
    • 8.2.2. Deracoxib
    • 8.2.3. Firocoxib
    • 8.2.4. Meloxicam
  • 8.3. Opioids
    • 8.3.1. Buprenorphine
    • 8.3.2. Fentanyl
    • 8.3.3. Tramadol

9. Companion Animal Postoperative Pain Management Therapeutics Market, by Animal Type

  • 9.1. Cats
  • 9.2. Dogs

10. Companion Animal Postoperative Pain Management Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical
  • 10.4. Transdermal Patch

11. Companion Animal Postoperative Pain Management Therapeutics Market, by End User

  • 11.1. Online Pharmacies
  • 11.2. Veterinary Hospitals And Clinics
    • 11.2.1. General Practices
    • 11.2.2. Specialty Hospitals
  • 11.3. Veterinary Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Companion Animal Postoperative Pain Management Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Postoperative Pain Management Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Postoperative Pain Management Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Companion Animal Postoperative Pain Management Therapeutics Market

16. China Companion Animal Postoperative Pain Management Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Addison Biological Laboratory Inc.
  • 17.6. Assisi Animal Health
  • 17.7. Avazzia
  • 17.8. Bayer AG
  • 17.9. Bimeda Animal Health
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. Cadila Healthcare Ltd.
  • 17.12. Ceva Sante Animale
  • 17.13. Chanelle Pharma Group
  • 17.14. Daiichi Sankyo Co. Ltd.
  • 17.15. Dechra Pharmaceuticals PLC
  • 17.16. Elanco Animal Health Incorporated
  • 17.17. Eltech K-Laser SRL
  • 17.18. Fidelis Pharmaceuticals, LLC
  • 17.19. Merck & Co.
  • 17.20. Multi Radiance Medical
  • 17.21. Norbrook Laboratories
  • 17.22. Richter Pharma AG
  • 17.23. SAVA Vet
  • 17.24. Sequent Scientific Ltd.
  • 17.25. VETINDIA Pharmaceuticals Limited
  • 17.26. Vetoquinol S.A.
  • 17.27. Virbac Group
  • 17.28. Virpax Pharmaceuticals Inc.
  • 17.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COMPANION ANIMAL POSTOPERATIV